Oncolytics Biotech Inc.

TSX:ONC Stock Report

Market Cap: CA$78.6m

Oncolytics Biotech Management

Management criteria checks 2/4

Oncolytics Biotech's CEO is Wayne Pisano, appointed in Jun 2024, has a tenure of less than a year. total yearly compensation is CA$424.23K, comprised of 24.1% salary and 75.9% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth CA$172.84K. The average tenure of the management team and the board of directors is 4.5 years and 5.9 years respectively.

Key information

Wayne Pisano

Chief executive officer

CA$424.2k

Total compensation

CEO salary percentage24.1%
CEO tenureless than a year
CEO ownership0.2%
Management average tenure4.5yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

Jan 28
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely?

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Feb 23
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Nov 10
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Jul 07
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Mar 24
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Deliver On Growth Plans?

Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

Dec 09
Is Oncolytics Biotech (TSE:ONC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Aug 25
We're Keeping An Eye On Oncolytics Biotech's (TSE:ONC) Cash Burn Rate

Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

May 12
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Dec 02
We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Aug 05
We Think Oncolytics Biotech (TSE:ONC) Can Afford To Drive Business Growth

Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

Apr 15
Companies Like Oncolytics Biotech (TSE:ONC) Are In A Position To Invest In Growth

We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

Dec 31
We Think Oncolytics Biotech (TSE:ONC) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Wayne Pisano's remuneration changed compared to Oncolytics Biotech's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024CA$424kCA$102k

-CA$32m

Sep 30 2024n/an/a

-CA$28m

Jun 30 2024n/an/a

-CA$28m

Mar 31 2024n/an/a

-CA$28m

Dec 31 2023CA$165kn/a

-CA$28m

Sep 30 2023n/an/a

-CA$32m

Jun 30 2023n/an/a

-CA$27m

Mar 31 2023n/an/a

-CA$24m

Dec 31 2022CA$150kn/a

-CA$25m

Sep 30 2022n/an/a

-CA$24m

Jun 30 2022n/an/a

-CA$24m

Mar 31 2022n/an/a

-CA$27m

Dec 31 2021CA$186kn/a

-CA$26m

Sep 30 2021n/an/a

-CA$28m

Jun 30 2021n/an/a

-CA$30m

Mar 31 2021n/an/a

-CA$29m

Dec 31 2020CA$160kn/a

-CA$23m

Sep 30 2020n/an/a

-CA$33m

Jun 30 2020n/an/a

-CA$29m

Mar 31 2020n/an/a

-CA$28m

Dec 31 2019CA$132kn/a

-CA$33m

Sep 30 2019n/an/a

-CA$19m

Jun 30 2019n/an/a

-CA$18m

Mar 31 2019n/an/a

-CA$17m

Dec 31 2018CA$147kn/a

-CA$17m

Compensation vs Market: Wayne's total compensation ($USD295.77K) is above average for companies of similar size in the Canadian market ($USD162.21K).

Compensation vs Earnings: Wayne's compensation has increased whilst the company is unprofitable.

CEO

Wayne Pisano (69 yo)

less than a year

Tenure

CA$424,227

Compensation

Mr. Wayne F. Pisano, MBA, is Interim Chief Executive Officer at Oncolytics Biotech Inc. since June 24, 2024. He has been an Independent Director of Altimmune, Inc. since August 30, 2018. Mr. Pisano had bee...

Leadership Team

NamePositionTenureCompensationOwnership
Wayne Pisano
Interim CEO & Chairman of the Boardless than a yearCA$424.23k0.22%
CA$ 172.8k
Kirk Look
Chief Financial Officer12.3yrsCA$1.01m0.16%
CA$ 124.9k
Thomas Heineman
Chief Medical Officer3.3yrsCA$1.17m0.15%
CA$ 121.1k
Allison Hagerman
Vice President of Product Development6.4yrsCA$635.84k0.073%
CA$ 57.6k
Amy Levin
Vice President of Clinical Operations2.2yrsCA$654.71kno data
Jon Patton
Director of Investor Relations & Communicationno datano datano data
Christophe Degois
Vice President of Business Developmentno datano data0.059%
CA$ 46.1k
John Lievonen
Consultant5.8yrsCA$25.98kno data

4.5yrs

Average Tenure

Experienced Management: ONC's management team is considered experienced (4.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Wayne Pisano
Interim CEO & Chairman of the Board11.8yrsCA$424.23k0.22%
CA$ 172.8k
Bernd Seizinger
Independent Director9.8yrsCA$103.35k0.44%
CA$ 345.9k
James Parsons
Independent Director2.8yrsCA$94.72kno data
Jonathan M. Rigby
Independent Director2.6yrsCA$87.52k0.36%
CA$ 286.5k
Patricia S. Andrews
Independent Director1.2yrsCA$108.36kno data
Angela Holtham
Independent Director10.8yrsCA$110.55k0.15%
CA$ 115.8k
Padmanee Sharma
Member of Scientific Advisory Boardno datano datano data
Dirk Arnold
Member of Scientific Advisory Board1.2yrsno datano data
Deborah Brown
Independent Director7.3yrsCA$104.79k0.057%
CA$ 44.5k
Martine Piccart
Member of Scientific Advisory Board7.3yrsno datano data
Richard Vile
Member of Scientific Advisory Board4.4yrsno datano data

5.9yrs

Average Tenure

66.5yo

Average Age

Experienced Board: ONC's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 01:28
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oncolytics Biotech Inc. is covered by 22 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeByron Capital Markets
Douglas LoeCantor Fitzgerald Canada Corporation
Douglas LoeEchelon Wealth Partners Inc.